It suppressed iNOS and NF-κB activation in glial cells, prevented astroglial and microglial oxidative injury in ex vivo systems, and inhibited microglial activation in lipopolysaccharide (LPS)–induced Parkinson’s disease (PD) models (Wang et al., 2002). Here, NOS2 is linked to Parkinson disease.